<DOC>
	<DOCNO>NCT00681551</DOCNO>
	<brief_summary>To verify number metastatic brain tumor detect contrast-enhanced MRI , primary variable , increase additional dose Magnevist ( SH L 451A ) comparing image initial dose ( 0.1 mmol/kg ) additional dose ( 0.1 mmol/kg , total dose 0.2 mmol/kg ) intra-individually patient metastatic brain tumor . Safety also assess .</brief_summary>
	<brief_title>Magnevist ( SH L 451A ) Intra-individual Dose Comparison Study Patients With Brain Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Patients confirm 15 metastatic brain tumor late contrastenhanced cerebral CT contrastenhanced cerebral MRI , lesion ( ) treat surgery stereotactic radiosurgery . Patients schedule receive another contrast medium MRI ( except oral agent ) iodine contrast medium ( except oral agent ) , undergo surgical procedure period day administration Magnevist ( SH L 451A ) examination safety follow day . Patients underwent scheduled undergo radiotherapy period 14 day administration Magnevist ( SH L 451A ) examination safety follow day . Patients treat schedule treated anticancer agent ( except treatment oral agent fix dose continuously 28 day administration Magnevist ( SH L 451A ) ) period 28 day administration Magnevist ( SH L 451A ) examination safety follow day .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Detection brain metastasis MRI</keyword>
	<keyword>Magnevist</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>Meglumine gadopentetate</keyword>
</DOC>